ATOS

Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut Pasteur

Retrieved on: 
Thursday, December 16, 2021

SEATTLE, Dec. 16, 2021 /PRNewswire/ -- Physician-Scientist Steven Quay, MD, PhD has published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021.

Key Points: 
  • SEATTLE, Dec. 16, 2021 /PRNewswire/ -- Physician-Scientist Steven Quay, MD, PhD has published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021.
  • The new research reports that BANAL-236 has evolved the ability to infect human cells by an unknown mechanism that violates over 40 years of coronavirus research.
  • "I contacted the Institut Pasteur with my findings and was deeply disturbed to learn that there was not, in fact, some simple mistake had occurred to explain things.
  • He is the author of the best-selling book on surviving the pandemic, Stay Safe: A Physician's Guide to Survive Coronavirus.

Atos and Dassault Systèmes to Deliver Trusted Sovereign Cloud Platform Experience for Critical Industries

Retrieved on: 
Thursday, December 9, 2021

Atos and Dassault Systmes today announce a global partnership to offer the 3DEXPERIENCE SaaS platform in a sovereign environment for critical and sensitive industries, notably in the defense and healthcare sectors.

Key Points: 
  • Atos and Dassault Systmes today announce a global partnership to offer the 3DEXPERIENCE SaaS platform in a sovereign environment for critical and sensitive industries, notably in the defense and healthcare sectors.
  • Customers will benefit from the cloud platform in a dedicated sovereign environment, which will be managed and secured by Atos.
  • Atos services rely on the Atos OneCloud Sovereign Shield , a set of methodologies, products and cloud services.
  • We are pleased to bring the Atos OneCloud Sovereign Shield to the SaaS applications domain, so we can offer a sovereign deployment of the 3DEXPERIENCE platform to critical industries worldwide.

Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration

Retrieved on: 
Monday, December 6, 2021

Holding a PIND meeting is a critical milestone in the regulatory pathway, said Dr. Heather Fraser, Atossas VP Clinical, Regulatory and CMC.

Key Points: 
  • Holding a PIND meeting is a critical milestone in the regulatory pathway, said Dr. Heather Fraser, Atossas VP Clinical, Regulatory and CMC.
  • We look forward to opening an IND in the second quarter of 2022 and then commencing a Phase 2 study in this setting.
  • Atossa also plans to conduct a pharmacokinetic run-in study as a part of the Phase 2 study to further define potential dose levels.
  • Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious diseases with a current focus on breast cancer and COVID-19.

Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 “A Town Hall Q&A Event With Atossa Therapeutics Management Team”

Retrieved on: 
Wednesday, November 24, 2021

During this complimentary event, Atossa management will speak at a Q&A session focused on Atossas research programs and future development.

Key Points: 
  • During this complimentary event, Atossa management will speak at a Q&A session focused on Atossas research programs and future development.
  • To join the complimentary event, please register at ATOSQA.TribePublic.com .
  • Once registered, Tribe members may then send their questions for Atossas management to [email protected] , which will be relayed during the event by Tribe Publics Managing Partner, John Heerdink.
  • Tribe Public LLC is a San Francisco, CA based organization that hosts complimentary worldwide webinar & meeting events in the U.S.

Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 15, 2021

SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended September 30, 2021, and provides an update on recent company developments.

Key Points: 
  • SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended September 30, 2021, and provides an update on recent company developments.
  • Key developments from Q3 2021 and to date include:
    Began to enroll participants in its clinical study of AT-H201 in Australia.
  • For the quarter ended September 30, 2021, Atossa has no source of sustainable revenue and no associated cost of revenue.
  • As of September 30, 2021, the Company had cash, cash equivalents and restricted cash of approximately $140 million.

Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month

Retrieved on: 
Thursday, October 21, 2021

SEATTLE, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Dr. Steven Quay, CEO of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today released a short video message recognizing Breast Cancer Awareness Month, and urging women to get mammograms.

Key Points: 
  • SEATTLE, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Dr. Steven Quay, CEO of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today released a short video message recognizing Breast Cancer Awareness Month, and urging women to get mammograms.
  • In the video message, which can be found on Atossas website here , Dr. Quay cites that the global pandemic changed everything with regard to breast cancer screening, indicating that many women have ceased to seek out their mammograms since the initial COVID-19 outbreak.
  • Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19.
  • For more information, please visit www.atossatherapeutics.com .

Approyo, Inc. Achieves Microsoft Gold Partner Status for Microsoft AZURE Cloud

Retrieved on: 
Tuesday, October 12, 2021

BROOKFIELD, Wis., Oct. 12, 2021 /PRNewswire/ --Approyo, Inc., a leader in global SAP & IT Managed Services and Solutions; today announced that it has attained Microsoft Gold Certified Partner status in the Microsoft Partner Program, with a competency in AZURE Cloud Platform .

Key Points: 
  • BROOKFIELD, Wis., Oct. 12, 2021 /PRNewswire/ --Approyo, Inc., a leader in global SAP & IT Managed Services and Solutions; today announced that it has attained Microsoft Gold Certified Partner status in the Microsoft Partner Program, with a competency in AZURE Cloud Platform .
  • The achievement of the Cloud Platform competency continues to highlight Approyo's expertise, evolution, and growing customer demand for managed infrastructure and software as a service (SaaS) solutions built on Microsoft AZURE Cloud.
  • As an advent of achieving Microsoft Gold Certification, more enterprise organizations choose Approyo for their managed IT services and migrations to Microsoft AZURE Cloud.
  • Approyo, Inc. is a Microsoft Gold Partner and an SAP-certified cloud, infrastructure, managed services, and SAP HANA operations services provider.

Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia

Retrieved on: 
Thursday, September 30, 2021

Up to one third of hospitalized patients have pulmonary function changes 60 days or more after recovering from COVID.

Key Points: 
  • Up to one third of hospitalized patients have pulmonary function changes 60 days or more after recovering from COVID.
  • The Phase 1/2a placebo-controlled study will enroll a total of 60 healthy participants and moderately-ill hospitalized COVID-19 patients.
  • The study is being conducted by Avance Clinical Pty Ltd., a leading Australian clinical research organization.
  • The Phase 1/2a study in Australia and other clinical studies must be successfully completed and regulatory approvals must be obtained before AT-H201 may be commercialized.

Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote

Retrieved on: 
Tuesday, September 7, 2021

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, has adjourned today’s special stockholder meeting to 9:00 a.m. Eastern time on October 7, 2021 to allow additional time for stockholders to vote. The Company urges stockholders to vote on the proposal put forth in the proxy statement prior to the new meeting date.

Key Points: 
  • The Company urges stockholders to vote on the proposal put forth in the proxy statement prior to the new meeting date.
  • The purpose of the special meeting is to approve an increase in authorized shares of common stock, which requires the affirmative vote of a majority of the shares of common stock issued and outstanding as of the record date.
  • Atossa is therefore adjourning the meeting for 30 days to allow additional time for stockholders to vote.
  • Leading proxy advisory firms ISS and Glass Lewis have recommended stockholders vote in favor of the proposed increase in authorized shares.

Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden

Retrieved on: 
Thursday, September 2, 2021

Additional studies show a correlation between reducing MBD and a reduction in the incidence of breast cancer.

Key Points: 
  • Additional studies show a correlation between reducing MBD and a reduction in the incidence of breast cancer.
  • Per Hall, a world leader in the field of breast density reduction, once again with our Endoxifen program.
  • The study, known as the Karisma-Endoxifen study, is a Phase 2, randomized, double-blind, placebo-controlled, dose-response study of Atossas proprietary oral Z-Endoxifen in healthy premenopausal women with increased breast density.
  • Atossa has been developing its proprietary oral Endoxifen for breast cancer and other breast conditions and has successfully completed four clinical studies with oral Endoxifen.